EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.
EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.
EAS 2019 Prof. Chris Packard distinguishes various types of biomarkers. Thinking about them in this way can provide a framework for more intelligent use of biomarkers.
EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.
EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.
EAS 2019 By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk. With poll
EAS 2019 Emerging evidence reveals that "HDL" represents an enormously heterogeneous mixture of particles, with varying structural, compositional, metabolic and functional properties.
EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.
EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality
EAS 2019 A consortium of Finnish, German and US centres performed GWAS, combined with phenome-wide scans, to integrate information from the lipidome, genome and phenome.
EAS 2019 Paul Ridker discusses the positive effect of canakinumab on, in particular, non-small cell lung cancer incidence and mortality, as demonstrated in the CANTOS trial.
EAS 2019 Heribert Schunkert and his team identified genetic variants that increase the risk of CAD. While many only exert a small effect, they did some striking observations on large increases of CV risk.